Ann: PAR Reports Successful Phase 2 Clinical Trial, page-48

No worries. As a side note, for completeness and balance I should add that Flexion can only be used once - so all other things efficacy and safety wise being equal, let alone better with iPPS we could expect substantially higher sales and valuations due to the repeat 'purchase' nature of PARs drug vs Flexion as toscanunan's anecdote re his wife highlights.  Tomorrow's trade could be telling for what the global market thinks... if it experiences a solid volume tomorrow (potentially indicative of overseas buying as BIT experienced) PAR could experience a rerate beyond what what I as an Australian based analyst think it probably fair value. That is, the market is not always perfectly efficient or consistent as some indications and companies are more attractive thematic wise or are simply better at IR and being good vision sellers and/or story tellers.